1 Castiello MC, Ferrari S, Villa A. Correcting inborn errors of immunity: from viral mediated gene addition to gene editing[J]. Semin Immunol, 2023, 66: 101731. PMID: 36863140. PMCID: PMC10109147. DOI: 10.1016/j.smim.2023.101731.
2 Arlabosse T, Booth C, Candotti F. Gene therapy for inborn errors of immunity[J]. J Allergy Clin Immunol Pract, 2023, 11(6): 1592-1601. PMID: 37084938. DOI: 10.1016/j.jaip.2023.04.001.
3 Pai SY, Logan BR, Griffith LM, et al. Transplantation outcomes for severe combined immunodeficiency, 2000-2009[J]. N Engl J Med, 2014, 371(5): 434-446. PMID: 25075835. PMCID: PMC4183064. DOI: 10.1056/NEJMoa1401177.
4 Tucci F, Galimberti S, Naldini L, et al. A systematic review and meta-analysis of gene therapy with hematopoietic stem and progenitor cells for monogenic disorders[J]. Nat Commun, 2022, 13(1): 1315. PMID: 35288539. PMCID: PMC8921234. DOI: 10.1038/s41467-022-28762-2.
5 Ott de Bruin LM, Lankester AC, Staal FJT. Advances in gene therapy for inborn errors of immunity[J]. Curr Opin Allergy Clin Immunol, 2023, 23(6): 467-477. PMID: 37846903. PMCID: PMC10621649. DOI: 10.1097/ACI.0000000000000952.
6 Friedmann T, Roblin R. Gene therapy for human genetic disease?[J]. Science, 1972, 175(4025): 949-955. PMID: 5061866. DOI: 10.1126/science.175.4025.949.
7 Blaese RM, Culver KW, Miller AD, et al. T lymphocyte-directed gene therapy for ADA- SCID: initial trial results after 4 years[J]. Science, 1995, 270(5235): 475-480. PMID: 7570001。 DOI: 10.1126/science.270.5235.475.
8 Ginn SL, Amaya AK, Alexander IE, et al. Gene therapy clinical trials worldwide to 2017: an update[J]. J Gene Med, 2018, 20(5): e3015. PMID: 29575374. DOI: 10.1002/jgm.3015.
9 Cring MR, Sheffield VC. Gene therapy and gene correction: targets, progress, and challenges for treating human diseases[J]. Gene Ther, 2022, 29(1-2): 3-12. PMID: 33037407. DOI: 10.1038/s41434-020-00197-8.
10 Tremblay JP, Annoni A, Suzuki M. Three decades of clinical gene therapy: from experimental technologies to viable treatments[J]. Mol Ther, 2021, 29(2): 411-412. PMID: 33472032. PMCID: PMC7854352. DOI: 10.1016/j.ymthe.2021.01.013.
11 Bulcha JT, Wang Y, Ma H, et al. Viral vector platforms within the gene therapy landscape[J]. Signal Transduct Target Ther, 2021, 6(1): 53. PMID: 33558455. PMCID: PMC7868676. DOI: 10.1038/s41392-021-00487-6.
12 Dogbey DM, Torres VES, Fajemisin E, et al. Technological advances in the use of viral and non-viral vectors for delivering genetic and non-genetic cargos for cancer therapy[J]. Drug Deliv Transl Res, 2023, 13(11): 2719-2738. PMID: 37301780. PMCID: PMC10257536. DOI: 10.1007/s13346-023-01362-3.
13 Kavanagh H, Dunne S, Martin DS, et al. A novel non-viral delivery method that enables efficient engineering of primary human T cells for ex vivo cell therapy applications[J]. Cytotherapy, 2021, 23(9): 852-860. PMID: 33941482. PMCID: PMC8386197. DOI: 10.1016/j.jcyt.2021.03.002.
14 Azarnezhad A, Samadian H, Jaymand M, et al. Toxicological profile of lipid-based nanostructures: are they considered as completely safe nanocarriers?[J]. Crit Rev Toxicol, 2020, 50(2): 148-176. PMID: 32053030. DOI: 10.1080/10408444.2020.1719974.
15 Gatti RA, Meuwissen HJ, Allen HD, et al. Immunological reconstitution of sex-linked lymphopenic immunological deficiency[J]. Lancet, 1968, 2(7583): 1366-9. PMID: 4177932. DOI: 10.1016/s0140-6736(68)92673-1.
16 Fischer A. Gene therapy for inborn errors of immunity: past, present and future[J]. Nat Rev Immunol, 2023, 23(6): 397-408. PMID: 36434109. DOI: 10.1038/s41577-022-00800-6.
17 Pai SY, Thrasher AJ. Gene therapy for X-linked severe combined immunodeficiency: historical outcomes and current status[J]. J Allergy Clin Immunol, 2020, 146(2): 258-261. PMID: 32561390. DOI: 10.1016/j.jaci.2020.05.055.
18 Aiuti A, Roncarolo MG, Naldini L. Gene therapy for ADA-SCID, the first marketing approval of an ex vivo gene therapy in Europe: paving the road for the next generation of advanced therapy medicinal products[J]. EMBO Mol Med, 2017, 9(6): 737-740. PMID: 28396566. PMCID: PMC5452047. DOI: 10.15252/emmm.201707573.
19 Tucci F, Scaramuzza S, Aiuti A, et al. Update on clinical ex vivo hematopoietic stem cell gene therapy for inherited monogenic diseases[J]. Mol Ther, 2021, 29(2): 489-504. PMID: 33221437. PMCID: PMC7854296. DOI: 10.1016/j.ymthe.2020.11.020.
20 Kohn DB, Booth C, Shaw KL, et al. Autologous ex vivo lentiviral gene therapy for adenosine deaminase deficiency[J]. N Engl J Med, 2021, 384(21): 2002-2013. PMID: 33974366. PMCID: PMC8240285. DOI: 10.1056/NEJMoa2027675.
21 Cowan MJ, Yu J, Facchino J, et al. Lentiviral gene therapy for Artemis-deficient SCID[J]. N Engl J Med, 2022, 387(25): 2344-2355. PMID: 36546626. PMCID: PMC9884487. DOI: 10.1056/NEJMoa2206575.
22 Garcia-Perez L, van Eggermond M, van Roon L, et al. Successful preclinical development of gene therapy for recombinase-activating gene-1-deficient SCID[J]. Mol Ther Methods Clin Dev, 2020, 17: 666-682. PMID: 32322605. PMCID: PMC7163047. DOI: 10.1016/j.omtm.2020.03.016.
23 Kohn LA, Kohn DB. Gene therapies for primary immune deficiencies[J]. Front Immunol, 2021, 12: 648951. PMID: 33717203. PMCID: PMC7946985. DOI: 10.3389/fimmu.2021.648951.
24 Ghanim HY, Porteus MH. Gene regulation in inborn errors of immunity: implications for gene therapy design and efficacy[J]. Immunol Rev, 2024, 322(1): 157-177. PMID: 38233996. DOI: 10.1111/imr.13305.
25 Albert MH, Slatter MA, Gennery AR, et al. Hematopoietic stem cell transplantation for Wiskott-Aldrich syndrome: an EBMT inborn errors working party analysis[J]. Blood, 2022, 139(13): 2066-2079. PMID: 35100336. DOI: 10.1182/blood.2021014687.
26 Vieira RC, Pinho LG, Westerberg LS. Understanding immunoactinopathies: a decade of research on WAS gene defects[J]. Pediatr Allergy Immunol, 2023, 34(4): e13951. PMID: 37102395. DOI: 10.1111/pai.13951.
27 Braun CJ, Boztug K, Paruzynski A, et al. Gene therapy for Wiskott-Aldrich syndrome: long-term efficacy and genotoxicity[J]. Sci Transl Med, 2014, 6(227): 227ra33. PMID: 24622513. DOI: 10.1126/scitranslmed.3007280.
28 Aiuti A, Biasco L, Scaramuzza S, et al. Lentiviral hematopoietic stem cell gene therapy in patients with Wiskott-Aldrich syndrome[J]. Science, 2013, 341(6148): 1233151. PMID: 23845947. PMCID: PMC4375961. DOI: 10.1126/science.1233151.
29 Labrosse R, Chu JI, Armant MA, et al. Outcomes of hematopoietic stem cell gene therapy for Wiskott-Aldrich syndrome[J]. Blood, 2023, 142(15): 1281-1296. PMID: 37478401. PMCID: PMC10731922. DOI: 10.1182/blood.2022019117.
30 Ferrua F, Marangoni F, Aiuti A, et al. Gene therapy for Wiskott-Aldrich syndrome: history, new vectors, future directions[J]. J Allergy Clin Immunol, 2020, 146(2): 262-265. PMID: 32623069. PMCID: PMC7453879. DOI: 10.1016/j.jaci.2020.06.018.
31 Cavazzana M, Thrasher A. Gene therapy for Whiskott-Aldrich syndrome: the latest news[J]. Clin Transl Med, 2022, 12(4): e815. PMID: 35437889. PMCID: PMC9016166. DOI: 10.1002/ctm2.815.
32 Laskowski TJ, Van Caeneghem Y, Pourebrahim R, et al. Gene correction of iPSCs from a Wiskott-Aldrich syndrome patient normalizes the lymphoid developmental and functional defects[J]. Stem Cell Reports, 2016, 7(2): 139-148. PMID: 27396937. PMCID: PMC4982969. DOI: 10.1016/j.stemcr.2016.06.003.
33 Rai R, Romito M, Rivers E, et al. Targeted gene correction of human hematopoietic stem cells for the treatment of Wiskott - Aldrich syndrome[J]. Nat Commun, 2020, 11(1): 4034. PMID: 32788576. PMCID: PMC7423939. DOI: 10.1038/s41467-020-17626-2.
34 Kohn DB, Booth C, Kang EM, et al. Lentiviral gene therapy for X-linked chronic granulomatous disease[J]. Nat Med, 2020, 26(2): 200-206. PMID: 31988463. PMCID: PMC7115833. DOI: 10.1038/s41591-019-0735-5.
35 Kohn DB, Rao GR, Almarza E, et al. A phase 1/2 study of lentiviral-mediated ex-vivo gene therapy for pediatric patients with severe leukocyte adhesion deficiency-I (LAD-I): results from phase 1[J]. Blood, 2020, 136, Supplement 1: 15. DOI: 10.1182/blood-2020-142484.
36 Borna S, Lee E, Sato Y, et al. Towards gene therapy for IPEX syndrome[J]. Eur J Immunol, 2022, 52(5): 705-716. PMID: 35355253. PMCID: PMC9322407. DOI: 10.1002/eji.202149210.
37 Lee PY, Aksentijevich I, Zhou Q. Mechanisms of vascular inflammation in deficiency of adenosine deaminase 2 (DADA2)[J]. Semin Immunopathol, 2022, 44(3): 269-280. PMID: 35178658. DOI: 10.1007/s00281-022-00918-8.
38 Lee PY, Davidson BA, Abraham RS, et al. Evaluation and management of deficiency of adenosine deaminase 2: an international consensus statement[J]. JAMA Netw Open, 2023, 6(5): e2315894. PMID: 37256629. DOI: 10.1001/jamanetworkopen.2023.15894.
39 Hashem H, Dimitrova D, Meyts I. Allogeneic hematopoietic cell transplantation for patients with deficiency of adenosine deaminase 2 (DADA2): approaches, obstacles and special considerations[J]. Front Immunol, 2022, 13: 932385. PMID: 35911698. PMCID: PMC9336546. DOI: 10.3389/fimmu.2022.932385.
40 Zoccolillo M, Brigida I, Barzaghi F, et al. Lentiviral correction of enzymatic activity restrains macrophage inflammation in adenosine deaminase 2 deficiency[J]. Blood Adv, 2021, 5(16): 3174-3187. PMID: 34424322. PMCID: PMC8405196. DOI: 10.1182/bloodadvances.2020003811.
41 Hong Y, Casimir M, Houghton BC, et al. Lentiviral mediated ADA2 gene transfer corrects the defects associated with deficiency of adenosine deaminase type 2[J]. Front Immunol, 2022, 13: 852830. PMID: 35529868. PMCID: PMC9073084. DOI: 10.3389/fimmu.2022.852830.
42 Vavassori V, Mercuri E, Marcovecchio GE, et al. Modeling, optimization, and comparable efficacy of T cell and hematopoietic stem cell gene editing for treating hyper-IgM syndrome[J]. EMBO Mol Med, 2021, 13(3): e13545. PMID: 33475257. PMCID: PMC7933961. DOI: 10.15252/emmm.202013545.